Tag: partnerships

LONDON, July 10, 2025 (GLOBE NEWSWIRE) -- ATFX Connect participated in the Duke of Edinburgh Cup City of London Qualifying Event, reaffirming our ongoing commitment to purpose-led partnerships and community-focused initiatives. As the Official Partner of the Duke of Edinburgh Cup, ATFX Connect continues to support this long-standing initiative, now in its eighth year, as part of our broader mission to give back through sport, education, and opportunity.

Aalst, Belgium, July 10, 2025 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, is proud to have been recognized by CDP* for the second time in a row for its climate actions in partnership with its suppliers, specifically aimed at reducing its scope 3 emissions. Ontex is among the highest-rated companies that are celebrated in the 2024 Supplier Engagement Leaderboard, which evaluates corporate supply chain engagement on climate issues. 

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that its seventh-generation (“Gen-7”) Robotaxi recently entered mass production for multiple models and began road testing. This milestone brings Pony.ai significantly closer to its goal of expanding its fleet to 1,000 vehicles by the end of 2025, laying a strong foundation for future large-scale commercial deployment.

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- YZi Labs, an investment vehicle fueling impact in Web3, AI, and biotech, today announced its support for 10X Capital, a leading investment firm focused on digital assets & digital asset treasury companies, in establishing the BNB Treasury Company, an independent U.S. initiative for digital asset treasury management on BNB Chain.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.